Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK0653A
MK0653A, ezetimibe simvastatin · 8 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| MK0653A, ezetimibe (+) simvastatin | DRUG | - |
| Duration of Treatment: 4 wk placebo run in then 6 wk active | DRUG | - |
| Comparator: atorvastatin | DRUG | - |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks | DRUG | - |
| Comparator: atorvastatin / Duration of Treatment: 6 Weeks | DRUG | - |
| MK0653A (ezetimibe [+] simvastatin) | DRUG | - |
| Comparator: fluvastatin | DRUG | - |
| Comparator: lovastatin | DRUG | - |
| Comparator: pravastatin | DRUG | - |
| Comparator: rosuvastatin | DRUG | - |
| Comparator: simvastatin | DRUG | - |
| MK0653A , ezetimibe (+) simvastatin | DRUG | - |
| Duration of Treatment: 6 weeks | DRUG | - |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks | DRUG | - |
| Comparators: simvastatin and ezetimibe | DRUG | - |
Inclusion Criteria: * Men and women aged 18 to 79 years who have a confirmed diagnosis of type 2 diabetes mellitus with elevated cholesterol levels may be eligible to participate in a study to assess the efficacy and safety of the two marketed drugs. Exclusion Criteria: * Type 1 Diabetes Mellitus...
MK0653A is a small molecule combination therapy studied for hypercholesterolemia and Type 2 diabetes mellitus. It combines ezetimibe and simvastatin and was evaluated in Phase 3 trials for lowering cholesterol in patients with these metabolic conditions, including those with both Type 2 diabetes and high cholesterol.
MK0653A is developed by Organon & Co., which trades under the ticker OGN. The company has sponsored six completed Phase 3 clinical trials of the ezetimibe and simvastatin combination, enrolling a total of 8,104 participants across studies in hypercholesterolemia and Type 2 diabetes mellitus.
MK0653A is in Phase 3 development. All six of its clinical trials are Phase 3 studies, and all six are completed, with no active trials currently listed. The program enrolled 8,104 participants in randomized, double-blind trials evaluating the ezetimibe and simvastatin combination.
MK0653A has been studied in six completed Phase 3 trials, including NCT00541697, a switch study in diabetics; NCT00132717, a 12-week study in patients hospitalized for a possible heart problem; NCT00110435, a multicenter cholesterol-lowering study in Type 2 diabetes and hypercholesterolemia; and NCT00092690, which compared MK0653A to atorvastatin for high cholesterol.
Yes, MK0653A is also known as ezetimibe simvastatin, ezetimibe (+) simvastatin, and ezetimibe (ezetimibe plus simvastatin). These names refer to the same combination product, which pairs ezetimibe with simvastatin. Some listings also include a duration of treatment, such as 6 weeks or 14 weeks, alongside the name.
MK0653A combines ezetimibe and simvastatin, two small molecules with complementary cholesterol-lowering actions. Simvastatin is a statin, and ezetimibe is a cholesterol absorption inhibitor. Together they target cholesterol metabolism through two distinct mechanisms to reduce cholesterol levels in patients with hypercholesterolemia and Type 2 diabetes mellitus.